title: RANK ligand.
abstract: RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells. In normal bone turnover and in bone metastasis, RANKL stimulates the formation and activity of bone-removing cells, osteoclasts, by binding to its cognate receptor, RANK, on osteoclasts and their progenitors; these processes are disrupted by binding of RANKL to osteoprotegerin (OPG), a soluble decoy receptor. Whilst no mutations in the RANKL gene have yet been identified in human disease, mutations that result in enhanced RANK signalling through inactivation of OPG or activation of RANK are associated with Juvenile Paget's disease and familial expansile osteolysis, respectively. This review focuses on the central role of RANKL in bone resorption and on the therapeutic targeting of RANKL in osteoporosis, humoral hypercalcaemia of malignancy and bone metastasis.
authors.affiliation: Molecular Bone Biology Laboratory, ANZAC Research Institute, University of Sydney at Concord Repatriation General Hospital, 1A Hospital Road, Concord, Sydney, NSW 2139, Australia. jblair@med.usyd.edu.au
authors.forename: J M
authors.initials: JM
authors.lastname: Blair
authors.forename: Y
authors.initials: Y
authors.lastname: Zheng
authors.forename: C R
authors.initials: CR
authors.lastname: Dunstan
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001862:Bone Resorption / Q000378:metabolism / Q000517:prevention & control; D020869:Gene Expression Profiling; D006801:Humans; D008954:Models, Biological; D008969:Molecular Sequence Data; D053244:Osteoprotegerin / Q000378:metabolism; D053245:RANK Ligand / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism*; D017386:Sequence Homology, Amino Acid
chemical_list: D053244:Osteoprotegerin; D053245:RANK Ligand